Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells

Blood

Volumn 105, Issue 6, 2005, Pages 2307-2315

  De Palma, Michele ^b   Montini, Eugenio ^b   Santoni De Sio, Francesca R ^b   Benedicenti, Fabrizio ^b   Gentile, Alessandra ^b   Medico, Enzo ^b   Naldini, Luigi ^a  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE; MURINE LEUKEMIA VIRUS; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROMOTER REGION; PROVIRUS; VIRUS EXPRESSION;

EID: 15244346492     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-0798     Document Type: Article

References (30)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint B, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669-672.
2. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415-419.
3. Williams DA, Baum C. Medicine. Gene therapy-new challenges ahead. Science. 2003;302:400-401.
4. Cavazzana-Calvo M, Thrasher A, Mavilio F. The future of gene therapy. Nature. 2004;427:779-781.
5. Fischer A, Abina SH, Thrasher A, von Kalle C, Cavazzana-Calvo M. LMO2 and gene therapy for severe combined immunodeficiency [letter]. N Engl J Med. 2004;350:2526-2527; author reply 2526-2527.
6. Schroder A, Shinn P, Chen H, Berry C, Ecker J, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110:521-9.
7. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300:1749-1751.
8. Laufs S, Gentner B, Nagy KZ, et al. Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood. 2003;101:2191-2198.
9. Medico E, Gambarotta G, Gentile A, Comoglio PM, Soriano P. A gene trap vector system for identifying transcriptionally responsive genes. Nat Biotechnol. 2001;19:579-582.
10. Roberts MR, Cooke KS, Tran AC, et al. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J Immunol. 1998;161:375-384.
11. Qiao J, Roy V, Girard MH, Caruso M. High translation efficiency is mediated by the encephalomyocarditis virus internal ribosomal entry sites if the natural sequence surrounding the eleventh AUG is retained. Hum Gene Ther. 2002;13:881-887.
12. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L. Coordinate dual-transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Natl Biotechnol. 2005;23:108-116.
13. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol. 1999;73:2886-2892.
14. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet. 2000;25:217-222.
15. De Palma M, Naldini L. Transduction of a gene expression cassette using advanced generation lentiviral vectors. Methods Enzymol. 2002;346:514-529.
16. Piacibello W, Bruno S, Sanavio F, et al. Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. Blood. 2002;100:4391-4400.
17. Ailles L, Schmidt M, Santoni de Sio FR, et al. Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/SCID repopulating hematopoietic cells. Mol Ther. 2002;6:615-626.
18. Schmidt M, Hoffmann G, Wissler M, et al. Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum Gene Ther. 2001;12:743-749.
19. Lavorgna G, Sessa L, Guffanti A, Lassandro L, Casari G. AntiHunter: searching BLAST output for EST antisense transcripts. Bioinformatics. 2004;20:583-585.
20. Wasserman WW, Sandelin A. Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet. 2004;5:276-287.
21. Martinez-Salas E. Internal ribosome entry site biology and its use in expression vectors. Curr Opin Biotechnol. 1999;10:458-464.
22. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther. 2000;1:376-382.
23. Cawley S, Bekiranov S, Ng HH, et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell. 2004;116:499-509.
24. Bushman FD. Targeting survival: integration site selection by retroviruses and LTR-retrotransposons. Cell. 2003;115:135-138.
25. Bestor TH. Gene silencing as a threat to the success of gene therapy. J Clin Invest. 2000;105:409-411.
26. Akagi K, Suzuki T, Stephens RM, Jenkins NA, Copeland NG. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res. 2004;32(database issue):D523-527.
27. Mikkers H, Berns A. Retroviral insertional mutagenesis: tagging cancer pathways. Adv Cancer Res. 2003;88:53-99.
28. Trono D. Virology. Picking the right spot. Science. 2003;300:1670-1671.
29. Mitchell RS, Beitzel BF, Schroder AR, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004;2:E234.
30. Imren S, Fabry ME, Westerman KA, et al. High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J Clin Invest. 2004;114:953-962.